Early Lyme disease

New England Journal of Medicine

Volumn 354, Issue 26, 2006, Pages 2794-2801

  Wormser, Gary P ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFALEXIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; DIETHYLTOLUAMIDE; DOXYCYCLINE; ERYTHROMYCIN; INSECT REPELLENT; ROXITHROMYCIN; ANTIINFECTIVE AGENT;

ARTHRALGIA; ARTICLE; BABESIOSIS; BORRELIA BURGDORFERI; CHOLELITHIASIS; CLINICAL TRIAL; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG ERUPTION; EHRLICHIOSIS; ERYTHEMA; ERYTHEMA CHRONICUM MIGRANS; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IXODES SCAPULARIS; LYME DISEASE; MALAISE; MENINGITIS; NECK PAIN; PHOTOSENSITIVITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; SEPSIS; SEROLOGY; SKIN DEFECT; TICK; TICK BITE; ADULT; ANIMAL; FEMALE; HISTOLOGY; IXODES; PRACTICE GUIDELINE; REVIEW;

ADULT; AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; CEFOTAXIME; DOXYCYCLINE; ERYTHEMA CHRONICUM MIGRANS; FEMALE; HUMANS; IXODES; LYME DISEASE; PRACTICE GUIDELINES;

EID: 33745591698     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp061181     Document Type: Article

References (51)

1. Lyme disease - United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2004;53:365-9.
2. O'Connell S, Granstrom M, Gray JS, Stanek G. Epidemiology of European Lyme borreliosis. Zentralbl Bakteriol 1998;287:229-40.
3. Wang G, van Dam AP, Schwartz I, Dankert J. Molecular typing of Borrelia burgdorferi sensu lato: taxonomic, epidemiological, and clinical implications. Clin Microbiol Rev 1999;12:633-53.
4. Steere AC, Sikand VK. The presenting manifestations of Lyme disease and the outcomes of treatment. N Engl J Med 2003;348:2472-4.
5. Nadelman RB, Wormser GP. Erythema migrans and early Lyme disease. Am J Med 1995;98:Suppl 4A:15S-24S.
6. Nadelman RB, Nowakowski J, Forseter G, et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med 1996;100:502-8.
7. Smith RP, Schoen RT, Rahn DW, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 2002;136:421-8.
8. Wormser GP, McKenna D, Carlin J, et al. Hematogenous dissemination in early Lyme disease. Ann Intern Med 2005;142:751-5.
9. Steere AC, Dhar A, Hernandez J, et al. Systemic symptoms without erythema migrans as the presenting picture of early Lyme disease. Am J Med 2003;114:58-62.
10. Schwartz I, Fish D, Daniels TJ. Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease. N Engl J Med 1997;337:49-50.
11. Falco RC, McKenna DF, Daniels TJ, et al. Temporal relation between Ixodes scapularis abundance and risk for Lyme disease associated with erythema migrans. Am J Epidemiol 1999;149:771-6.
12. Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001;345:79-84.
13. Falco RC, Fish D, Piesman J. Duration of tick bites in a Lyme disease-endemic area. Am J Epidemiol 1996;143:187-92.
14. Piesman J, Maupin GO, Campos EG, Happ CM. Duration of adult female Ixodes dammini attachment and transmission of Borrelia burgdorferi with description of a needle aspiration isolation method. J Infect Dis 1991;163:895-7.
15. Ohnishi J, Piesman J, de Silva AM. Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks. Proc Natl Acad Sci U S A 2001;98:670-5.
16. Steere AC, Bartenhagen NH, Craft JE, et al. The early clinical manifestations of Lyme disease. Ann Intern Med 1983;99:76-82.
17. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987;107:725-31.
18. Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis 2000;31:Suppl 1:1-14.
19. Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of Lyme borreliosis. Clin Microbiol Rev 2005;18:484-509.
20. Wormser GP, Masters E, Nowakowski J, et al. Prospective clinical evaluation of patients from Missouri and New York with erythema migrans-like skin lesions. Clin Infect Dis 2005;41:958-65.
21. Ryder JW, Pinger RR, Glancy T. Inability of Ixodes cookei and Amblyomma americanum nymphs (Acari: Ixodidae) to transmit Borrelia burgdorferi. J Med Entomol 1992;29:525-30.
22. Keirans JE, Lacombe EH. First records of Ambylomma americanum, Ixodes (Ixodes) dentatus, and Ixodes (Ceratixodes) uriae (Acari: Ixodidae) from Maine. J Parasitol 1998;84:629-31.
23. Armstrong PM, Brunet LR, Spielman A, Telford SR III. Risk of Lyme disease: perceptions of residents of a Lone Star tick-infested community. Bull World Health Organ 2001;79:916-25.
24. Schulze TL, Bowen GS, Bosler EM, et al. Amblyomma americanum: a potential vector of Lyme disease in New Jersey. Science 1984;224:601-3.
25. Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep 1997;46(RR-10):20-1.
26. Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol 1996;34:1-9.
27. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995;44:590-1.
28. Engstrom SM, Shoop E, Johnson RC. Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. J Clin Microbiol 1995;33:419-27.
29. Johnson BJ, Robbins KE, Bailey RE, et al. Serodiagnosis of Lyme disease: accuracy of a two-step approach using flagella-based ELISA and immunoblotting. J Infect Dis 1996;174:346-53.
30. Steere AC, McHugh G, Suarez C, Hoitt J, Damle N, Sikand VK. Prospective study of coinfection in patients with erythema migrans. Clin Infect Dis 2003;36:1078-81.
31. Belongia EA, Reed KD, Mitchell PD, et al. Clinical and epidemiological features of early Lyme disease and human granulocytic ehrlichiosis in Wisconsin. Clin Infect Dis 1999;29:1472-7.
32. Krause PJ, McKay K, Thompson CA, et al. Disease-specific diagnosis of coinfecting tick-borne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. Clin Infect Dis 2002;34:1184-91.
33. Krause PJ, Telford SR III, Spielman A, et al. Concurrent Lyme disease and babesiosis: evidence for increased severity and duration of illness. JAMA 1996;275:1657-60.
34. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann Intern Med 1996;124:785-91.
35. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992;117:273-80.
36. Hayes EB, Piesman J. How can we prevent Lyme disease? N Engl J Med 2003;348:2424-30.
37. Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:697-704.
38. Nowakowski J, Nadelman RB, Sell R, et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med 2003;115:91-6.
39. Dattwyler RJ, Luft BJ, Kunkel M, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 1997;337:289-94.
40. Eckman MH, Steere AC, Kalish RA, Pauker SG. Cost effectiveness of oral as compared with intravenous antibiotic treatment for patients with early Lyme disease or Lyme arthritis. N Engl J Med 1997;337:357-63.
41. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of early manifestations of Lyme disease. Ann Intern Med 1983;99:22-6.
42. Hansen K, Hovmark A, Lebech A-M, et al. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm Venereol 1992;72:297-300.
43. Nowakowski J, McKenna D, Nadelman RB, et al. Failure of treatment with cephalexin for Lyme disease. Arch Fam Med 2000;9:563-7.
44. Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob Agents Chemother 1992;36:1788-90.
45. Sood SK, Salzman MB, Johnson BJB, et al. Duration of tick attachment as a predictor of the risk of Lyme disease in an area in which Lyme disease is endemic. J Infect Dis 1997;175:996-9.
46. Wormser GP, Fish D. Lyme disease. In: Baddour LM, Gorbach SL, eds. Therapy of infectious diseases. Philadelphia: Saunders, 2003:697-719.
47. Falco RC, McKenna D, Nowakowski J, Nadelman R, Wormser GP, Daniels TJ. Evaluation of patient assessment of tick bite duration and eligibility for Lyme disease prophylaxis in a clinical setting. In: Programme of the 10th International Conference on Lyme Borreliosis and Other Tick-borne Diseases, Vienna, September 11-15, 2005:120. abstract.
48. Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998;339:209-15.
49. Shapiro ED, Dattwyler R, Nadelman RB, Wormser GP. Response to meta-analysis of Lyme borreliosis symptoms. Int J Epidemiol 2005;34:1437-9.
50. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345:85-92.
51. Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? Neurology 2003;60:1916-22.